Table 4.

Changes in monthly headache and migraine days (Mean ± SD of MHDs and MMDs) at 90 days.

Study Report (Author and Year)	Comparator/Baseline Change in MHDs	Comparator/Baseline Change in MMDs	Intervention Dose 1 Change in MHDs	Intervention Dose 2 Change in MHDs	Intervention Dose 1 Change in MMDs	Intervention Dose 2 Change in MMDs
Armanious et al., 2021 [46]	n = 34/78 8.1 ± 8.8	n = 33/78 7.4 ± 6.8	Erenumab 70 mg n = 21/37 8.3 ± 8.7 Improvement over baseline in 56.8% of treated patients	Erenumab 140 mg n = 13/41 7.8 ± 9.3	Erenumab 70 mg n = 19/37 6.7 ± 5.6	Erenumab 140 mg n = 14/41 8.4 ± 8.2 Improvement over baseline in 34.1% of treated patients